BioCryst Pharmaceuticals, Inc. (BCRX) Guidance & Earnings Results

On 2026-08-05 BioCryst Pharmaceuticals, Inc. raised guidance: "FY26 ORLADEYO revenue maintained $625-645M; FY26 total revenue raised to $690-715M from $635-660M; FY26 non-GAAP operating expense improved to $420-440M from…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BCRXBioCryst Pharmaceuticals, Inc.Follow BCRX — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 2.0B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	FY26 ORLADEYO revenue maintained $625-645M; FY26 total revenue raised to $690-715M from $635-660M; FY26 non-GAAP operating expense improved to $420-440M from $450-470M · full year
26 Feb 26	Reaffirmed	ORLADEYO revenue guidance $625-645M for FY2026 · full year
12 Jan 26	Raised	FY2026 ORLADEYO revenue guidance $625-645M vs FY2025 actual $601M
3 Nov 25	Raised	FY2025 ORLADEYO revenue guidance raised to $590-600M; non-GAAP operating expense guidance lowered to $430-440M. · full year
4 Aug 25	Reaffirmed	FY2025 global net ORLADEYO revenue $580-600M; non-GAAP operating expenses $440-450M; net income and positive cash flow expected for full year 2025. · full year

BioCryst Pharmaceuticals, Inc. — questions

What guidance did BioCryst Pharmaceuticals, Inc. give?: On 2026-08-05: "FY26 ORLADEYO revenue maintained $625-645M; FY26 total revenue raised to $690-715M from $635-660M; FY26 non-GAAP operating expense improved to $420-440M from $450-470M"
When does BioCryst Pharmaceuticals, Inc. report earnings?: BioCryst Pharmaceuticals, Inc.'s next earnings report is expected on 2026-11-04.

Every figure on this page comes from BioCryst Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.